Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression Kuvan Nonresponders (IST)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01274026|
Recruitment Status : Unknown
Verified January 2011 by Tulane University School of Medicine.
Recruitment status was: Recruiting
First Posted : January 11, 2011
Last Update Posted : January 11, 2011
This study seeks to establish evidence:
- that physiologic changes, unrelated to effect on the PAH enzyme, occur in PKU patients who are treated with Kuvan® therapy,
- that these changes may be caused by enhanced neurotransmitter synthesis in the brain or an upregulation of gene expression (increasing the ability of genes to produce functional enzymes),
- and that beneficial changes in behavior and cognition, especially executive functioning skills may result.
The objective of this study is to correlate any change in behavior and executive function skills of PKU patients who are non-responsive to sapropterin effect on the PAH enzyme, as defined by lowered blood PHE levels, with urine neurotransmitter levels and broad gene expression prior to and after sapropterin administration.
Expected outcomes would include evidence of sapropterin effects on upregulation of enzymes other than PAH that control neurotransmitter synthesis, and any resulting correlation with behavioral and cognitive changes.
The investigators hope this study will inform further detailed investigations into the biochemical and molecular actions of sapropterin (Kuvan®) that lead to increased understanding of possible treatment effects beyond a lowered blood PHE response.
|Condition or disease||Intervention/treatment||Phase|
|Phenylketonuria Behavior and Behavior Mechanisms PAH Gene Expression||Drug: sapropterin dihydrochloride||Not Applicable|
The study participant population will include approximately 30 established PKU patients receiving care from Hayward Genetics Center, who were found previously to exhibit no decrease in blood PHE levels (nonresponders) with administration of sapropterin. Subjects will act as their own controls. Primary endpoints will be measurement of behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity after 4 weeks on treatment compared to baseline levels.
At study baseline each patient will attend an approximately 1 hour clinic visit at their usual genetics clinic location. Study purpose, design, and requirements will be discussed, and consents/assents reviewed and signed.
Rating inventories of executive function performance and behavior (BASC-2 and BRIEF tools) will be administered to patients and parents by the PI and/or the Study Coordinator.
Urine samples will be collected non-invasively for measurement of neurotransmitter levels. Blood will be collected by venipuncture (3-5 ml) for microarray expression analysis and analysis of plasma amino acids. 3-day food records previously provided to participants for completion will be collected.
Participants will be provided with a 4 week supply of Kuvan® and instructions on how to take the medication during the study period. The importance of maintaining usual dietary intake (food choices and metabolic formula) to minimize any research effect not attributable to sapropterin administration will be emphasized. Sapropterin will be discontinued at the end of the 4 week study period.
All of these measures will be repeated at the same sites with study participants at the end of week 4 of the study period.
At the ends of weeks 1 and 2 additional blood samples will be sent to Hayward Genetics Center for measurement of PHE and TYR levels to ascertain no significant changes have occurred in a patient's usuual dietary intake. These samples will be drawn at each patient's local state health unit, as is done for usual monitoring. Nutrient analysis of the 3-day food diaries will be conducted at Hayward Genetics Center.
- Behavior and executive function will be assessed using published validated inventories for ages 2-21 years, completed as patient self-reports and as parent (or guardian) reports when appropriate. Instruments used will be the Behavioral Assessment System for Children (BASC-2) parental Rating Scale and Self-Reporting Personality Rating Scale, and the Behavioral Rating Inventory of Executive Function (BRIEF) Parent Form Instruments of Executive Function. Completed inventories will be scored using electronic evaluation instruments by the Study Coordinator and PI, with consultation from Harvard Medical Center experts as needed.
- Urine samples will be non-invasively collected and sent for analysis of catechols and neurotransmitters to an NIH laboratory specializing in this technique. Samples will be blinded to prevent bias.
- Microarray analysis of blood samples will be conducted at Hayward Genetics Molecular Laboratory to determine any effect on gene expression, and thus enzyme activity, as a result of sapropterin administration.
- Plasma amino acids will be analyzed at Hayward Genetics Biochemical Laboratory to document that patients are "nonresponsive" to sapropterin (no resultant lowering of blood PHE); and to monitor any changes in plasma amino acids that could indicate a patient's failure to maintain usual dietary restrictions
- 3-day food diaries completed by patients (or parent/guardians) at home will document any substantive changes in usual dietary intake during the study period. These will be analyzed at Hayward Genetics Center using the MetabolicPro web-based analysis program.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Behavior, Executive Function, Neurotransmitter Function and Genomic Expression in PKU "Nonresponders" to Kuvan® (Sapropterin Dihydrochloride)|
|Study Start Date :||January 2011|
|Estimated Primary Completion Date :||August 2011|
|Estimated Study Completion Date :||January 2012|
- Drug: sapropterin dihydrochloride
In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.
Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted.Other Name: Kuvan
- change in behavior and/or executive function as a result of Kuvan administration [ Time Frame: assessment during a 4 week trial of Kuvan ]
This study seeks to establish evidence:
that behavioral and cognitive changes, unrelated to blood phenylalanine levels, occur in PKU patients who are treated with Kuvan® therapy, and that beneficial changes in behavior and congnition, especially executive functioning skills as measured by validated measurement questionnaires may result.
- change in neurotransmitter synthesis [ Time Frame: assessment during a 4 week trial of Kuvan administration ]
This study seeks to establish evidence:
that physiologic changes, unrelated to effect on the PAH enzyme, occur in PKU patients who are treated with Kuvan® therapy,and that these changes may be caused by enhanced neurotransmitter synthesis in the brain or an upregulation of gene expression (increasing the ability of genes to produce functional enzymes), Expected outcomes would include evidence of sapropterin effects on upregulation of enzymes other than PAH that control neurotransmitter synthesis, and any resulting correlation with behavioral and cognitive changes.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01274026
|Contact: Amy Cunningham, MSemail@example.com|
|Contact: Hans Andersson, MDfirstname.lastname@example.org|
|United States, Louisiana|
|Tulane University Health Science Center||Recruiting|
|New Orleans, Louisiana, United States, 70112|
|Principal Investigator: Hans Andersson, MD|
|Sub-Investigator: Amy Cunningham, MS|